GeoVax Labs (NASDAQ:GOVX) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reissued their buy rating on shares of GeoVax Labs (NASDAQ:GOVX) in a report issued on Monday, Benzinga reports. They currently have a $8.00 price objective on the stock.

Other equities analysts have also issued research reports about the company. EF Hutton Acquisition Co. I raised GeoVax Labs to a strong-buy rating in a research report on Tuesday, July 23rd. Roth Capital raised GeoVax Labs to a strong-buy rating in a research report on Tuesday, July 16th. Finally, Roth Mkm began coverage on GeoVax Labs in a research report on Tuesday, July 16th. They issued a buy rating and a $20.00 price target for the company.

GeoVax Labs Trading Up 3.1 %

NASDAQ:GOVX opened at $3.35 on Monday. The firm’s fifty day simple moving average is $2.40 and its 200 day simple moving average is $2.15. GeoVax Labs has a twelve month low of $1.09 and a twelve month high of $9.75.

GeoVax Labs (NASDAQ:GOVX) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($1.99) earnings per share for the quarter, beating the consensus estimate of ($2.57) by $0.58. The company had revenue of $0.30 million during the quarter. During the same quarter in the prior year, the business posted ($3.30) EPS. On average, analysts expect that GeoVax Labs will post -7.41 EPS for the current year.

Hedge Funds Weigh In On GeoVax Labs

A hedge fund recently bought a new stake in GeoVax Labs stock. Armistice Capital LLC bought a new stake in shares of GeoVax Labs, Inc. (NASDAQ:GOVX) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,626,516 shares of the company’s stock, valued at approximately $587,000. Armistice Capital LLC owned 91.38% of GeoVax Labs as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 6.09% of the company’s stock.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.